Head-to-head · WeighScore
Ascend Vitality vs Nucific
The verdict
Ascend Vitality takes it — 60.9/100 to 56.2/100.
Ascend Vitality grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ascend Vitality is a cash-pay GLP-1 telehealth provider offering compounded semaglutide (starting at $199/mo) and compounded tirzepatide (starting at $299/mo) as both weekly injectables and needle-free…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ascend Vitality | Nucific |
|---|---|---|
| WeighScore | 60.9/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #307 | #417 |
| Semaglutide | $199/mo (compounded) | Not disclosed |
| Tirzepatide | $299/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #307 · C
Strengths
- Both injectable and needle-free oral tablet forms of semaglutide and tirzepatide
- LegitScript certified
- Transparent cash-pay pricing with cancel-anytime subscription
- Legal entity and address publicly disclosed (Ascend Vitality LLC, Sheridan, WY)
Where it loses points
- All medications are compounded — FDA does not review compounded drugs for safety/effectiveness
- No named compounding pharmacy partner disclosed
- No public state-by-state availability list (homepage cites exclusions: LA, MS, KS, NM, WV)
- Per-dose/titration pricing not published; only 'starting at' prices shown
Graded #417 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.